The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma

International Journal of Gynecological Cancer

Volumn 11, Issue 2, 2001, Pages 119-129

  Skirnisdottir I ^a,b,c   Sorbe, B ^a,b,c   Seidal, T ^a,b,c  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b ÖREBRO MEDICAL CENTRE HOSPITAL   (Sweden)

^c CENTRAL HOSPITAL   (Sweden)

Author keywords

EGFR; Growth factor receptors; HER 2 neu; Ovarian cancer; Prognostic factors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLEAR CELL CARCINOMA; FEMALE; GENE EXPRESSION; GENE THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; ONCOGENE NEU; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS;

CARCINOMA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; REGRESSION ANALYSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0035027576     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2001.011002119.x     Document Type: Article

References (43)

1. Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer
2. Molecular and biological factors in the pathogenesis of ovarian cancer
3. Conclusions and recommendations from the Helene Harris Memorial Trust sixth biennial international forum on ovarian cancer. May 10-14, 1997, Los Angeles, California, USA
4. Human ovarian cancer of the surface epithelium
5. Cell growth regulation in ovarian cancer: Tyrosine kinases, tyrosine phophatases and tumour necrosis factor-α
6. HER-2/neu signal transduction in human breast and ovarian cancer
7. Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns
8. Molecular approaches to diagnosis and management of ovarian cancer
9. Immunohistochemical assessment of proliferation markers and altered gene expression in archival specimens of ovarian epithelial tumors
10. Overexpression of the oncogene c-erbB2 (HER2/neu) in ovarian cancer: A new prognostic factor
11. Overexpression of the oncogene cerb-B2 (HER-2/neu) and response to chemotherapy in patients with ovarian cancer
12. Identification of differentially expressed genes associated with HER-2/neu overexpression in human breast cancer cells
13. Expression of the erbB family of receptors in ovarian cancer
14. Growth factors and receptors in ovarian cancer
15. The N-terminal 178-amino-acid domain only of the SV40 large T antigen acts as a transforming suppressor of the HER-2/neu oncogene
16. Coexpression of the HER-2 gene product p185 (HER2) and epidermal growth factor receptor p175 (EGF-R) on epithelial ovarian cancers and normal tissues
17. Tumors of the ovary, maldeveloped gonads, fallopian tube and broad ligament
18. The histological grading of neoplasms
19. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures
20. HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma
21. The roles of oncogenes in ovarian cancer
22. The expression of c-erbB-2 (HER-2/neu) oncogene in invasive ovarian malignancies
23. Studies of HER-2/ neu proto-oncogene in human breast and ovarian cancer
24. C-erbB-2 oncoprotein assay in ovarian carcinoma and its clinical correlation with prognostic factors
25. Exression of cerbB-2, c-myc and c-ras oncoproteins, insulin-like growth receptor I and epidermal growth factor receptor in ovarian carcinoma
26. The prognostic value of epidermal growth factor receptors, determined by both immunohistochemistry and ligand binding assays in primary epithelial ovarian cancer: A pilot study
27. NEU protein overexpression in benign, borderline and malignant ovarian neoplasms
28. Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokine activated killer cells: Correlation with expression of HER2/ neu oncogene
29. An immunohistochemical study of the incidence and significance of cerbB-2 oncoprotein overexpression in ovarian neoplasia
30. Overexpression of the oncogene cerbB-2 in primary ovarian cancer: Evaluation of the prognostic value in a Cox proportional hazards multiple regression
31. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer
32. Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: A multivariate analysis
33. Overexpression and relationship of HER-2/neu, epidermal growth factor receptor, p53, Ki-67, and tumor necrosis factor alpha in epithelial ovarian cancer
34. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer
35. EGF-R and overexpression of the oncogene c-erbB-2 in ovarian cancer: Immunohistochemical findings and prognostic value
36. Epidermal growth factor receptor and c-erbB-2 oncoproteins in tissue and tumor effusion cells of histopathologically different ovarian neoplasms
37. Epidermal growth factor reduces HER-2 protein level in human ovarian carcinoma cells
38. Biological therapy of ovarian cancer: Current directions
39. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs
40. Radioiodinated antibody targeting of the HER-2/neu oncoprotein: Effects of labeling method on cellular processing and tissue distribution
41. Augmentation of humanized anti-HER-2 MAb 4D5 induced inhibition by a human-mouse chimeric anti-EGF receptor MAb C225
42. Epidermal growth factor-mediated targeting of chlorin e6 selectively potentiates its photodynamic activity
43. Anti-tumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies